Sequential Dialysis Technique
COVID-19
Key Facts
About Halberd
Halberd Corporation (OTC: HALB) is a publicly traded, pre-revenue biotechnology company founded in 2018 with a mission to develop novel 'subtractive' therapies for hard-to-treat diseases. Its core strategy leverages patented extracorporeal filtration technologies, licensed from Marv Enterprises, to remove causative agents like viruses, toxins, and misfolded proteins from bodily fluids. Recent achievements include initiating research collaborations with Arizona State University and Mississippi State University, and the 2025 acquisition of NeuroSense AI Corp. to augment its neuroscience assessment capabilities. The company maintains an ambitious, wide-ranging pipeline spanning COVID-19, sepsis, cancer, PTSD, and CTE, though all programs remain in pre-clinical discovery and development.
View full company profileAbout Halberd
Halberd Corporation (OTC: HALB) is a publicly traded, pre-revenue biotechnology company founded in 2018 with a mission to develop novel 'subtractive' therapies for hard-to-treat diseases. Its core strategy leverages patented extracorporeal filtration technologies, licensed from Marv Enterprises, to remove causative agents like viruses, toxins, and misfolded proteins from bodily fluids. Recent achievements include initiating research collaborations with Arizona State University and Mississippi State University, and the 2025 acquisition of NeuroSense AI Corp. to augment its neuroscience assessment capabilities. The company maintains an ambitious, wide-ranging pipeline spanning COVID-19, sepsis, cancer, PTSD, and CTE, though all programs remain in pre-clinical discovery and development.
View full company profileAbout Halberd
Halberd Corporation (OTC: HALB) is a publicly traded, pre-revenue biotechnology company founded in 2018 with a mission to develop novel 'subtractive' therapies for hard-to-treat diseases. Its core strategy leverages patented extracorporeal filtration technologies, licensed from Marv Enterprises, to remove causative agents like viruses, toxins, and misfolded proteins from bodily fluids. Recent achievements include initiating research collaborations with Arizona State University and Mississippi State University, and the 2025 acquisition of NeuroSense AI Corp. to augment its neuroscience assessment capabilities. The company maintains an ambitious, wide-ranging pipeline spanning COVID-19, sepsis, cancer, PTSD, and CTE, though all programs remain in pre-clinical discovery and development.
View full company profileAbout Halberd
Halberd Corporation (OTC: HALB) is a publicly traded, pre-revenue biotechnology company founded in 2018 with a mission to develop novel 'subtractive' therapies for hard-to-treat diseases. Its core strategy leverages patented extracorporeal filtration technologies, licensed from Marv Enterprises, to remove causative agents like viruses, toxins, and misfolded proteins from bodily fluids. Recent achievements include initiating research collaborations with Arizona State University and Mississippi State University, and the 2025 acquisition of NeuroSense AI Corp. to augment its neuroscience assessment capabilities. The company maintains an ambitious, wide-ranging pipeline spanning COVID-19, sepsis, cancer, PTSD, and CTE, though all programs remain in pre-clinical discovery and development.
View full company profileAbout Halberd
Halberd Corporation (OTC: HALB) is a publicly traded, pre-revenue biotechnology company founded in 2018 with a mission to develop novel 'subtractive' therapies for hard-to-treat diseases. Its core strategy leverages patented extracorporeal filtration technologies, licensed from Marv Enterprises, to remove causative agents like viruses, toxins, and misfolded proteins from bodily fluids. Recent achievements include initiating research collaborations with Arizona State University and Mississippi State University, and the 2025 acquisition of NeuroSense AI Corp. to augment its neuroscience assessment capabilities. The company maintains an ambitious, wide-ranging pipeline spanning COVID-19, sepsis, cancer, PTSD, and CTE, though all programs remain in pre-clinical discovery and development.
View full company profileAbout Halberd
Halberd Corporation (OTC: HALB) is a publicly traded, pre-revenue biotechnology company founded in 2018 with a mission to develop novel 'subtractive' therapies for hard-to-treat diseases. Its core strategy leverages patented extracorporeal filtration technologies, licensed from Marv Enterprises, to remove causative agents like viruses, toxins, and misfolded proteins from bodily fluids. Recent achievements include initiating research collaborations with Arizona State University and Mississippi State University, and the 2025 acquisition of NeuroSense AI Corp. to augment its neuroscience assessment capabilities. The company maintains an ambitious, wide-ranging pipeline spanning COVID-19, sepsis, cancer, PTSD, and CTE, though all programs remain in pre-clinical discovery and development.
View full company profileAbout Halberd
Halberd Corporation (OTC: HALB) is a publicly traded, pre-revenue biotechnology company founded in 2018 with a mission to develop novel 'subtractive' therapies for hard-to-treat diseases. Its core strategy leverages patented extracorporeal filtration technologies, licensed from Marv Enterprises, to remove causative agents like viruses, toxins, and misfolded proteins from bodily fluids. Recent achievements include initiating research collaborations with Arizona State University and Mississippi State University, and the 2025 acquisition of NeuroSense AI Corp. to augment its neuroscience assessment capabilities. The company maintains an ambitious, wide-ranging pipeline spanning COVID-19, sepsis, cancer, PTSD, and CTE, though all programs remain in pre-clinical discovery and development.
View full company profileTherapeutic Areas
Other COVID-19 Drugs
| Drug | Company | Phase |
|---|---|---|
| COVID-19 Severity Prediction Test | Age Labs | Development |
| PanCytoVir™ (oral probenecid) | TrippBio | Phase 2 |
| OT-101 | Sapu BioScience | Clinical Trial (Phase not specified) |
| Idylla SARS-CoV-2 Test | Biocartis | Approved |
| Adjuvanted Cell-Based COVID-19 Vaccine | CSL Seqirus | Marketed |
| Amubarvimab + Romlusevimab (BRII-196/BRII-198) | Brii Biosciences | Approved |
| COVID-19 Vaccine Testing (for AstraZeneca) | Advaxia Biologics | Approved |
| COVID-19 Vaccine Clinical Batches | Advaxia Biologics | Clinical |
| UOL COVID-19 Test | Uh-Oh Labs | Approved |
| Lagevrio (molnupiravir) | Ridgeback Biotherapeutics | Approved/EUA |
| CVXGA | CyanVac | Phase 2 |
| SARS-CoV-2 Test | NanoPin Technologies | Commercial (LDT) |